A. H. Briggs

Ethanol acceptance as a function of genotype amounts of brain [Met]enkephalin.

Blum, K, Elston, S F, DeLallo, L, Briggs, A H, Wallace, J E

Our results indicate a negative correlation between the amount of ethanol (10%) consumed and endogenous levels of brain [Met]enkephalin in C57BL/6J (alcohol-preferring) and DBA/2J...

Management of urinary tract infection in general practice: a cost-effectiveness analysis.

Fenwick, E A, Briggs, A H, Hawke, C I

BACKGROUND: Symptoms associated with urinary tract infection (UTI) are common in women in general practice and represent a significant burden for the National Health Service. There is considerable...

Ethanol acceptance as a function of genotype amounts of brain [Met]enkephalin.

Blum, K, Elston, S F, DeLallo, L, Briggs, A H, Wallace, J E

Our results indicate a negative correlation between the amount of ethanol (10%) consumed and endogenous levels of brain [Met]enkephalin in C57BL/6J (alcohol-preferring) and DBA/2J...

Management of urinary tract infection in general practice: a cost-effectiveness analysis.

Fenwick, E A, Briggs, A H, Hawke, C I

BACKGROUND: Symptoms associated with urinary tract infection (UTI) are common in women in general practice and represent a significant burden for the National Health Service. There is considerable...

Cost effectiveness of screening for and eradication of Helicobacter pylori in management of dyspeptic patients under 45 years of age.

Briggs, A. H., Sculpher, M. J., Logan, R. P., Aldous, J., Ramsay, M. E., Baron, J. H.

OBJECTIVE--To assess the cost effectiveness of screening for and eradicating Helicobacter pylori in patients under 45 years of age presenting with dyspepsia. DESIGN--A decision analytic model...

Thinking outside the box: recent advances in the analysis and presentation of uncertainty in cost-effectiveness studies

Briggs, A.H., O'Brien, B.J., Blackhouse, G.

As many more clinical trials collect economic information within their study design, so health economics analysts are increasingly working with patient-level data on both costs and effects. In this...

Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease

Briggs, A.H., Goeree, R., Blackhouse, G., O'Brien, B.J.

When choosing between mutually exclusive treatment options, it is common to construct a cost-effectiveness frontier on the cost-effectiveness plane that represents efficient points from among the...

The death of cost-minimization analysis?

Briggs, A.H., O'Brien, B.J.

Four different types of evaluation methods, cost-benefit analysis (CBA), cost-utility analysis (CUA), cost-effectiveness analysis (CEA) and cost-minimization analysis (CMA), are usually...

Estimating the cost-effectiveness of fluticasone propionate for treating chronic obstructive pulmonary disease in the presence of missing data

Briggs, A.H., Lozano-Ortega, G., Spencer, S., Bale, G., Spencer, M.D., Burge, S.

Objectives: To explore the cost-effectiveness of fluticasone propionate (FP) for the treatment of chronic obstructive pulmonary disease (COPD), we estimated costs and quality-adjusted life-years...

Parametric modelling of cost data: some simulation evidence

Briggs, A.H., Nixon, R., Dixon, S., Thompson, S.

Recently, commentators have suggested that the distributional form of cost data should be explicitly modelled to gain efficiency in estimating the population mean. We perform a series of simulation...

Statistical approaches to handling uncertainty in health economic evaluation

Briggs, A.H.

Not so long ago, uncertainty in economic evaluation was handled almost exclusively using simple one-way sensitivity analysis methods whereby individual parameters of an analysis were varied...

Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people

Mihaylova, B., Briggs, A.H., Armitage, J., Parish, S., Gray, A., Collins, R.

Objectives: To evaluate the cost effectiveness of 40 mg simvastatin daily continued for life in people of different ages with differing risks of vascular disease. Design A model developed from a...

Development and validation of a prognostic index for health outcomes in chronic obstructive pulmonary disease

Briggs, A.H., Spencer, M., Wang, H., Mannino, D.

Background: Chronic obstructive pulmonary disease (COPD) is a debilitating and progressive disease. The severity of the condition has typically been characterized by a single physiological...

The credibility of health economic models for health policy decision-making: the case of population screening for abdominal aortic aneurysm

Campbell, H., Briggs, A.H., Buxton, M., Kim, L., Thompson, S.

Objectives: To review health economic models of population screening for abdominal aortic aneurysm (AAA) among elderly males and assess their credibility for informing decision-making. Methods: A...

Probabilistic sensitivity analysis for NICE technology assessment: not an optional extra

Claxton, K., Sculpher, M., McCabe, C., Briggs, A.H., Akehurst, R., Buxton, M., ...

Recently the National Institute for Clinical Excellence (NICE) updated its methods guidance for technology assessment. One aspect of the new guidance is to require the use of probabilistic...

Cost-effectiveness of asthma control: an economic appraisal of the GOAL study

Briggs, A.H., Bousquet, J., Wallace, M.V., Busse, W.W., Clark, T.J.H., Pedersen, S.E., ...

Background: The Gaining Optimal Asthma ControL (GOAL) study has shown the superiority of a combination of salmeterol/fluticasone propionate (SFC) compared with fluticasone propionate alone (FP) in...

Uterine artery embolisation or hysterectomy for the treatment of symptomatic uterine fibroids: a cost-utility analysis of the HOPEFUL study

Wu, O., Briggs, A.H., Dutton, S., Hirst, A., Maresh, M., Nicholson, A., ...

Objectives To evaluate the relative cost-effectiveness of uterine artery embolisation (UAE) and hysterectomy in women with symptomatic uterine fibroids from the perspective of the UK NHS. Design...

A Bayesian approach to aid in formulary decision making: incorporating institution-specific cost-effectiveness data with clinical trial results

Reed, S.D., Dillingham, P.W., Briggs, A.H., Veestra, D.L., Sullivan, S.D.

Pharmacy and therapeutics committees commonly cite a lack of generalizability as a reason for not incorporating cost-effectiveness information into decision making. To address this concern, many...

A Bayesian approach to stochastic cost-effectiveness analysis

Briggs, A.H.

The aim of this paper is to discuss the use of Bayesian methods in cost-effectiveness analysis (CEA) and the common ground between Bayesian and traditional frequentist approaches. A further aim is to...

Affordability and cost-effectiveness: decision-making on the cost-effectiveness plane

Sendi, P.P, Briggs, A.H.

Much recent research interest has focused on handling uncertainty in cost-effectiveness analysis and in particular the calculation of confidence intervals for incremental cost-effectiveness ratios...

Analysis of uncertainty in health care cost-effectiveness studies: an introduction to statistical issues and methods

O'Brien, B.J., Briggs, A.H.

Cost-effectiveness analysis is now an integral part of health technology assessment and addresses the question of whether a new treatment or other health care program offers good value for money. In...

Assessing generalisability by location in trial-based cost-effectiveness analysis: the use of multilevel models

Manca, A., Rice, N., Sculpher, M.J., Briggs, A.H.

Cost-effectiveness analysis (CEA) in health care is increasingly conducted alongside multicentre and multinational randomised controlled clinical trials (RCTs). The increased use of stochastic CEA is...